Étiquette : Oncology

CEVIDRA

by jbertholdin Biotech, Pharma

CEVIDRA

About the company

Founded 17 years ago, Cevidra is an independent pharmaceutical company with a strong expertise in hospital affairs, particularly in tenders, and a vast network of experts. As a rapidly growing entity in the early access domain, Cevidra acts as a gateway to the French market for foreign companies. Rooted in innovation, agility, and commitment, Cevidra offers comprehensive services from its headquarters in Grasse, with additional offices in Paris and Lyon.

Holding GDP/GMP certifications, it excels as an « Exploitant » for pharmaceutical products, specializing in distribution through its logistical platform. Cevidra provides services ranging from regulatory affairs to market access and real-world data collection. It has a strong track record in managed access programs across various areas, including ATMPs.

About the solution

As an Exploitant with an in-house GDP platform, Cevidra offers flexible support to foreign companies launching medicines in France. They handle compassionate/early access programs, market approval, and distribution, including market access and promotional activities in hospitals and pharmacies. Their tailored approach ensures a seamless entry into the French market.

Website
Key information

–  Therapeutic areas: All therapeutic areas including Oncology, Rare diseases and Addictive medicine.

–  Based in: Grasse, Lyon and Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2007

ALGENSCRIBE

by jbertholdin Biotech, Pharma

ALGENSCRIBE

About the company

Algenscribe operates in the field of Gene Editing: the company is developing a new platform for Gene Replacement with its first applications in Gene Therapy and Oncology.

About the solution

The aim is to achieve the full potential of Gene Editing for Gene Replacement. Algenscribe’s technologies address two major constraints of the field: the number of cells edited is significantly increased, while certain undesirable effects are reduced.

Website
Key information

–  Therapeutic areas: Gene Editing, Gene Therapy, Oncology

–  Based in: Gif sur Yvette & Nice (FRANCE)

–  Employees: 1 – 10

–  Created in: 2022

XENOTHERA

by jbertholdin Biotech, Pharma

XENOTHERA

About the company

XENOTHERA is a clinical stage biotech company developing First-In-Class drugs mainly in oncology and hematology.

Their disruptive immunotherapy, based on a patented platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb), addresses major unmet medical needs, especially in solid and liquid tumors. Accelerated development is made possible due to scaled-up commercial grade industry, regulatory and clinical expertise, and in-house bioproduction facility.

About the solution

XENOTHERA develops two main assets: LIS1, in Peripheral T-cell lymphoma (First Patient expected Q2 2024) and in Solid Organ Transplantation (confirmatory pivotal trial in preparation) and XON7, a pan-cancer GH-pAb targeting solid tumors, currently in Phase I/II.

Website
Key information

–  Therapeutic areas: Oncology, Acute Graft rejection

–  Based in: Nantes (FRANCE)

–  Employees: 11 – 50

–  Created in: 2014

SYNDIVIA

by jbertholdin Biotech, Pharma

SYNDIVIA

About the company

Syndivia is dedicated to enhancing treatment options for patients with solid tumors. They specialize in utilizing their proprietary and unique GeminiMab™ technology — the first and only hinge-region Cys229 site-specific ADC technology applicable to native monoclonal antibodies. Specifically, they take advantage of the distinctive GeminiMab™-DAR1 ADCs, which offer improved antitumor efficacy and reduced toxicity.

About the solution

The key technology behind Syndivia’s unique site-specific approach is GeminiMab™, the first and only technology for hinge-region site-specific conjugation (2xCys229), enabling unprecedented efficiency and scope in creating site-specific DAR1 ADCs.

Their proprietary candidates include:

1. SDV2102: GeminiMab anti-PSMA ADC (mCRPC, GBM, HCC)

2. SDV2103: GeminiMab anti-Trop2 ADC (NSCLC)

Website
Key information

–  Therapeutic areas: Antibody-drug-conjgutes, Oncology

–  Based in: Strasbourg (FRANCE)

–  Employees: 1 – 10

–  Created in: 2014

FIRALIS MOLECULAR PRECISION

by jbertholdin Biotech, Pharma

FIRALIS MOLECULAR PRECISION

About the company

Firalis Molecular Precision (FMP), established in 2019 and rooted in the Firalis Group, operates as a leading Contract Research Organization (CRO) from Huningue, France.

Specialized in biomarker discovery and multi-omic analysis (genomics, proteomics, metabolomics), FMP accelerates precision medicine by improving diagnostics, understanding disease mechanisms, and evaluating drug efficacy. With advanced laboratories and a dedicated team of over 55 experts, FMP supports biotech and pharma companies globally, offering a suite of services that span pre-clinical to clinical trials, thus playing a pivotal role in advancing healthcare innovations.

About the solution

Firalis Molecular Precision (FMP) is at the forefront of the multi-omics revolution bringing progress and innovation to the biopharmaceutical industry. By harnessing advanced -omics technologies and bioinformatics, they excel in identifying promising therapeutic targets and enhancing the drug development process for greater speed and reliability. Their state-of-the-art multi-omics solutions facilitate precise, high-throughput genomics, transcriptomics, and proteomics, leading to pioneering healthcare breakthroughs.

Website
Key information

–  Therapeutic areas: Neurology, Oncology, Immunology  

–  Based in: Huningue (FRANCE) & Cambridge (USA)

–  Employees: 51 – 200

–  Created in: 2016

HERMERION THERAPEUTICS

by jbertholdin Biotech, Medtech, Pharma

HERMERION THERAPEUTICS

About the company

Hemerion was created in 2020, after more than 10 years of academic research carried out in an INSERM laboratory in association with Lille University Hospital in France. They are developing a first-line treatment for newly diagnosed Glioblastoma (GBM) that integrates with surgery before the administration of adjuvant therapies.

Their mission is to deliver novel therapies that aim at significantly improving the overall survival and quality of life of GBM patients.

Hemerion is an award-winning HealthTech company:

– In 2021 they received the Galien MedStartup Prize for « Best Collaboration in the MedTech and Digital Health » category. The Galien MedStartup fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of the most promising French startups, selected by a world-renowned panel, and connects them with leading American businesses.

– In 2023 they were awarded the Golden Ticket Ipsen Biolabs at the Biotech incubator Hotel Dieu Paris, granting them access to biology laboratories to enable the development of preclinical research in glioblastoma.

About the solution

They are developing a first-in-class therapeutic approach for glioblastoma (GBM), the most common malignant brain tumor in adults with 156,000 new cases worldwide per year. Their strategy is promising to significantly improve GBM care management through its unique properties:

– They combine a photonic device (Heliance® Solution) and a drug (Pentalafen®), a photosensitizing agent, which has a therapeutic effect when illuminated with red light.

– This approach represents a breakthrough one-time intervention enabling the destruction of residual tumor cells, responsible for tumor recurrence, following surgery resection.

– It is harmless for healthy tissues as Pentalafen® preferentially accumulates in tumor cells to selectively destroy them.

All in all, their innovation is a novel and safe mechanism of action significantly improving GBM upfront care management by only adding 30 minutes to the current care workflow. Their solution is a photodynamic therapy approach for GBM patients undergoing surgery and seamlessly fits into any patient continuum of care.

Website
Key information

–  Therapeutic areas: Oncology, Neuro-Oncology, Brain Tumor, Neurosurgery

–  Based in: Lille & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2020

AFFILOGIC

by jbertholdin Biotech, Pharma

AFFILOGIC

About the company

Affilogic is a private, French biotech company established in 2010. They are specialized in discovering and developing Nanofitins® through collaborations with worldwide industry leaders in the pharmaceutical sector.

About the solution

Nanofitins are small, hyperstable affinity proteins, which can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.

Website
Key information

–  Therapeutic areas: Infectiology, Oncology, CNS disorders, Inflammatory diseases

–  Based in: Nantes (FRANCE)

–  Employees: 11 -50

–  Created in: 2010

CHELATEC

by jbertholdin Biotech, Pharma

CHELATEC

About the company

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

About the solution

Their services cover/include:
– Bioconjugation
– Radioactive labeling
– Analytical controls (HPLC, iTLC/TLC, SDS-PAGE…)
– Stability studies (storage stability, plasma stability)
– In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
– In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

Website
Key information

–  Therapeutic areas: Oncology, Targeted therapy

–  Based in: Saint-Herblain (FRANCE)

–  Employees: 11 -50

–  Created in: 2000

CYNBIOSE

by jbertholdin Biotech, CRO/CDMO, Pharma

CYNBIOSE

About the company

Cynbiose is a preclinical CRO specialized in non-human primate (NHP) translational models for biomedical research since 2008. They maintain a France-based AAALAC-accredited animal facility for toxicological studies. Their brand new state-of-the-art facility can also accommodate studies requiring biosafety environments from ABSL-1 to 3, as well as GMOs such as viral vector-based gene therapies.

About the solution

The NHP model is well suited to predict pharmacokinetic and pharmacodynamic parameters, guide the selection of a safe starting dose for FIH trials, and provide valuable data on the potential toxicity of the candidate.

Their non-GLP preclinical services include:

– Pharmacokinetics (PK, central pharmacokinetics) and pharmacodynamics (PD) profiles

– In vivo biodistribution studies: biodistribution pattern (tissues, fluids such as CSF), Kpuu determination, and non-invasive imaging technologies

– Preclinical safety assessment, DRF, MTD, immunotoxicity, immunogenicity studies

– Immunopharmacology models

– Dedicated solutions: Nose-to-brain delivery strategies, Inhaled products, Gene therapies

Their state-of-the-art France-based animal facility has been AAALAC accredited since 2015. Their proven platform can operate studies in biosafety levels up to level 3, as well as GMOs C1-2, in a GLP-like environment.

Cynbiose combines ten years of preclinical experience and a wide range of cutting-edge capabilities to serve biopharmaceutical companies. Driven by passion and curiosity for science, their sponsors value them as trusted, reliable, flexible, and innovative partners.

Website
Key information

–  Therapeutic areas: Central nervous system (CNS), Oncology, Infectious diseases, Respiratory diseases, Immune disorders & inflammation

–  Based in: Marcy l’Etoile (FRANCE)

–  Employees: 11 -50

– Created in: 2008

ALTEVAX BIOTECH

by jbertholdin Biotech, Pharma

ALTEVAX BIOTECH

About the company

ALTEVAX was founded in 2016 by Professor Antoine Carpentier, neuro-oncologist and Head of the Neurology Department at Saint-Louis Hospital in Paris (AP-HP). His research on biological nanoparticles and melanin’s potential as adjuvant for vaccines resulted in a patented antigen-melanin platform technology.

Since 2016, the research team at ALTEVAX has demonstrated melanin’s ability to shield antigens from degradation and transport them to the lymph nodes, where they induce a robust and specific immune response involving CD4 and CD8. ALTEVAX technology is protected by two families of general patents and can be used in a wide range of new vaccines depending on the antigens selected.

ALTEVAX lead product, a therapeutic vaccine against Glioblastoma, based on the tumor-associated antigen TERT (from the telomerase complex), has completed the final stage of preclinical development, and will enter a Phase 1/2a clinical trial in newly diagnosed glioblastoma in Q3 2024.

About the solution

ALTEVAX technology, peptide-based vaccines using melanin as adjuvant triggers a specific immune response, involving CD4+ and CD8+ lymphocytes, against self-antigens that is more effective and faster than current vaccine technology using emulsions, RNA (primarily producing antibodies and few CD8+), or DNA as messenger vectors. Laboratory experiments confirmed its superior efficacy.

Melanin induces an immune reaction similar to the reaction by the human body when defending against pathogenic aggressions. It is a natural, non-toxic product and offers an excellent benefit-to-risk ratio.

ALTEVAX mastered the production process for synthetic melanin and its combination with peptides. Its vaccines will be administered subcutaneously, simplifying administration, and reducing costs.

Website
Key information

–  Therapeutic areas: Oncology, Therapeutic Vaccine, Immuno-Oncology, Immunotherapy, Adjuvant Platform, Glioblastoma

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2016